<p><strong>Diuretics</strong>: Co-administration of Empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.<br />
<br />
<strong>Insulin or Insulin Secretagogues</strong>: Co-administration of Empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia.<br />
<br />
<strong>Positive Urine Glucose Test</strong>: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.<br />
<br />
<strong>Drugs that Reduce Metformin Clearance</strong>: Drugs that reduce Metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of Metformin.<br />
<br />
<strong>Carbonic Anhydrase Inhibitors</strong>: Carbonic anhydrase inhibitors may increase risk of lactic acidosis.<br />
<br />
<strong>Drugs Affecting Glycemic Control</strong>: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid produce hoperglycemia. When such drugs are administered to a patient receiving Empagliflozin and Metformin combination, the patient should be closely observed to maintain adequate glycemic control. When such drugs are withdrawn from a patient receiving Empagliflozin and Metformin combination, the patient should be observed closely for hypoglycemia.<br />
<br />
<strong>Alcohol</strong>: Alcohol can potentiate the effect of Metformin on lactate metabolism. Warn patients against excessive alcohol intake.</p>